Leukocyte Adhesion Deficiency Management Market Report 2026

The leukocyte adhesion deficiency management market size has grown strongly in recent years. It will grow from $8.59 billion in 2025 to $9.16 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to limited treatment options for rare immunodeficiency disorders, high infection-related mortality rates, reliance on antimicrobial therapy, low awareness of leukocyte adhesion deficiency, restricted access to advanced transplantation facilities.

The leukocyte adhesion deficiency management market size is expected to see strong growth in the next few years. It will grow to $12.2 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to advancements in stem cell transplantation techniques, increasing availability of genetic testing, rising investment in rare disease research, growing adoption of personalized immunotherapy, expansion of specialized immunology care centers. Major trends in the forecast period include expansion of hematopoietic stem cell transplantation, rising adoption of gene-based diagnostic testing, growing use of prophylactic immunoglobulin therapy, increasing focus on early infection prevention, advancements in targeted immunomodulatory treatments.

The increasing prevalence of primary immunodeficiency is expected to drive the growth of the leukocyte adhesion deficiency management market in the coming years. Primary immunodeficiency (PID) is a group of inherited disorders that impair the body's immune system, making individuals more vulnerable to infections and illnesses due to defects in their immune responses. Management of leukocyte adhesion deficiency supports primary immunodeficiency by enhancing the understanding of immune system disorders and potentially contributing to the development of better diagnostic tools and therapies for both conditions. For example, in April 2023, data from World Primary Immunodeficiency (WPI) Awareness Week 2023, collected by Peace Hospital, an India-based multi-specialty hospital, indicated that primary immunodeficiency (PI) affects an estimated 6 million people globally, with 70% to 90% of cases remaining undiagnosed. Thus, the growing prevalence of primary immunodeficiency is expected to fuel the growth of the leukocyte adhesion deficiency management market.

Major companies in the leukocyte adhesion deficiency management market are focusing on developing lentiviral vector-based gene therapy technology to enhance targeted treatments and improve patient outcomes. Lentiviral vector-based gene therapy provides a precise approach in leukocyte adhesion deficiency management by delivering corrective genes directly into cells, potentially restoring immune function. For example, in February 2024, Rocket Pharmaceuticals, a US-based biotechnology company, introduced kresladi (marnetegragene autotemcel) for the treatment of severe leukocyte adhesion deficiency-I (LAD-I). In a Phase 1/2 study, it demonstrated 100% survival at 12 months, significantly reducing infections and improving symptoms. Kresladi represents a pioneering option in the LAD management market, addressing critical unmet needs.

In February 2023, Jeffrey Modell Foundation (JMF), a US-based nonprofit organization for primary immunodeficiency, partnered with Veritas Intercontinental to advance genome and exome sequencing for immunological disorders. The collaboration aims to improve precise diagnosis and treatment by globally identifying gene abnormalities in primary immunodeficiency, including leukocyte adhesion deficiency. Veritas Intercontinental is a Spain-based healthcare solutions company specializing in genome sequencing and analytical services.

Major companies operating in the leukocyte adhesion deficiency management market are F. Hoffmann-La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Gilead Sciences Inc, Teva Pharmaceuticals Industries Limited, CSL Behring LLC, Vertex Pharmaceuticals Inc., Grifols International S.A., Aurobindo Pharma Ltd., BioMarin Pharmaceutical Inc., Cadila Healthcare Ltd., Ipca Laboratories Ltd, Sana Biotechnology Inc., Rocket Pharmaceuticals Inc., PT Sanbe Farma, Magenta Therapeutics Inc, Avalo Therapeutics Inc., Aspen Neuroscience Inc., Sandoz International GmbH, Orpha Labs Inc., Swiss Pharm Holding AG, Rubius Therapeutics Inc., Enochian Biosciences Inc., Sigma-Aldrich LLC, Bluebird Bio Inc.

North America was the largest region in the leukocyte adhesion deficiency management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukocyte adhesion deficiency management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leukocyte adhesion deficiency management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the leukocyte adhesion deficiency management market by increasing costs of imported biologics, immunoglobulins, monoclonal antibodies, and transplantation-related medical supplies. Treatment segments such as hematopoietic stem cell transplantation, recombinant biologics, and prophylactic immunotherapies are most affected, particularly in north america and europe due to dependence on cross-border biopharmaceutical supply chains. Higher procurement costs may strain hospital budgets and specialty clinic resources. However, tariffs have encouraged domestic biologics manufacturing, regional clinical research initiatives, and long-term strengthening of local rare-disease treatment infrastructure.

The leukocyte adhesion deficiency management market research report is one of a series of new reports that provides leukocyte adhesion deficiency management market statistics, including leukocyte adhesion deficiency management industry global market size, regional shares, competitors with a leukocyte adhesion deficiency management market share, detailed leukocyte adhesion deficiency management market segments, market trends and opportunities, and any further data you may need to thrive in the leukocyte adhesion deficiency management industry. This leukocyte adhesion deficiency management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Leukocyte adhesion deficiency (LAD) is a rare inherited disorder that impairs the immune system's ability to combat infections. It involves a defect in the adhesion (stickiness) of white blood cells, particularly neutrophils, which are crucial for defending the body against bacteria and fungi. Management of leukocyte adhesion deficiency generally requires a multidisciplinary approach, focusing on preventing and treating infections as well as addressing the underlying immune system dysfunction.

The main types of treatment in leukocyte adhesion deficiency management include hematopoietic stem cell transplantation, recombinant human interferon-gamma therapy, prophylactic immunoglobulin therapy, antimicrobial therapy, preventive therapy, fucose supplementation, monoclonal antibodies, and coagulation factors. Hematopoietic stem cell transplantation is a medical procedure in which stem cells from the bone marrow or blood are transplanted into a patient to replace damaged or diseased blood-forming cells. Treatments and diagnostics, including blood tests, genetic testing, biopsies, and others, are provided by end users such as hospitals, specialty clinics, and other healthcare facilities.

The leukocyte adhesion deficiency management market consists of revenues earned by entities by providing services such as gene therapy, granulocyte transfusions, nutrition, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The leukocyte adhesion deficiency management market also includes sales of antibiotics such as trimethoprim and sulfamethoxazole. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.